Track topics on Twitter Track topics that are important to you
BMT elucidates modulation of host defense mechanisms responsible for inflammatory and autoimmune diseases. The major disease areas in which BMT is conducting research are atherosclerosis, rheumatoid arthritis and certain forms of allergies. With a staff of more than 50 researchers and initial € 12 million of corporate and public funding, BMT generates break-through innovations which can be turned into marketable intellectual property rights. BMT provides attractive new technologies which are ready for industrial applications and which have substantial spin-off potential.
As a joint venture between the industrial partners Baxter, Technoclone and Polymun and academic partners from the Medical University Vienna and the University of Natural Resources and Applied Life Sciences, Vienna, BMT not only receives substantial funding (in-kind and cash) from pharmaceutical industry, but also contributes from the intellectual power of outstanding scientists from renowned academic institutes.
Brunner Strasse 59,
Delivery of the Report will take 23 working days once order is placed.The Global Biomolecular Motor Market Research Report Forecast 20172022 is a valuable source of insightful data for business strate...
Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.
A team of chemical and biomolecular engineers at the University of Notre Dame designed nanoparticles that mimic natural allergens by displaying each allergic component one at a time on their surfaces
By exploiting a brain tumor's own biology, researchers at FIU's Biomolecular Sciences Institute (BSI) are hoping to destroy glioblastoma, a deadly brain cancer with no known cure.
Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.
A new review by David A. Walsh and Joanne Stocks in the September 2017 issue of SLAS Discovery (formerly the Journal of Biomolecular Screening) explores evolving treatments and future therapies for os...
ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...
ALDEX GS™ Tablets
ALDEX GS DMTablets
Metal complexes that catalyze inactivation and degradation of biomolecular targets can be developed into novel therapeutics (catalytic metallodrugs) against a variety of diseases. Despite recent advan...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.
The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...
Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...
A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.
We have published hundreds of BioMolecular Therapeutics news stories on BioPortfolio along with dozens of BioMolecular Therapeutics Clinical Trials and PubMed Articles about BioMolecular Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics Companies in our database. You can also find out about relevant BioMolecular Therapeutics Drugs and Medications on this site too.
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...